Prothena Biosciences Limited

PRTA · Nasdaq · Ireland

Share price · PRTA

$8.35-0.36 (-4.13%) 3M

close as of 2026-11-18 · 24h delayed · vol 764K (1.5x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when PRTA's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 9 Nov 2026+10.1%

    Nothing announced by PRTA that day or the session before.

  2. 21 Oct 2026-5.5%

    Nothing announced by PRTA that day or the session before.

  3. 7 Oct 2026+5.7%
  4. 30 Sep 2026-4.6%
  5. 24 Sep 2026-4.1%
  6. 11 May 2026-9.9%
  7. 28 Apr 2026+6.7%
  8. 2 Mar 2026+8.4%

Share of unusual movement by asset

For each asset, the share of PRTA's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Prasinezumab
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—2%
Other company news (earnings, financing, releases naming no asset)—24%
Sessions with no dated event—74%

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
alpha-synucleinMonoclonal antibody
Parkinson's Disease
Phase 2
Tau (monoclonal antibody)Monoclonal antibody
Alzheimer's Disease

Discontinued programmes (1)

Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
MoponetugPhase 2Alzheimer Disease, Early Onset
Est. primary completion 2026-12-17 · NCT06268886 · CT.gov ↗
What to watch
2029 (1)
June 2029 (1)
PrasinezumabPhase 3Parkinson's Disease
Est. primary completion 2029-06-30 · NCT07174310 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 August 2025Topline resultPRX012PRX012 Phase 1 ASCENT program results: amyloid lowering with high ARIA-E rates
Prothena Corporation plc · Source ↗
23 May 2025Topline resultbirtamimabPhase 3 AFFIRM-AL of birtamimab did not meet its primary endpoint
Prothena Biosciences Limited · Source ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$0.6M$8.4M$272M$17M-$12M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$1.0M$8.8M$289M$19M-$25M operating cash flowreport ↗
2026-Q1$51M—$330M—report ↗
2025-Q3$2.4M$29M$332M$37M-$41M operating cash flowreport ↗
2025-Q2$4.4M$41M$372M$126M-$46M operating cash flowreport ↗
2025-Q1$2.8M$51M$419M$60M-$53M operating cash flowreport ↗
2024-Q3$1.0M$51M$520M$59M-$45M operating cash flowreport ↗
2024-Q2$132M$58M$565M—$16M operating cash flowreport ↗
2024-Q1$0.1M$64M$549M$72M-$73M operating cash flowreport ↗
2023-Q3$85M$58M$673M—$9.5M operating cash flowreport ↗
2023-Q2$4.0M$56M$661M$55M-$45M operating cash flowreport ↗
2023-Q1$2.2M$45M$688M$47M-$47M operating cash flowreport ↗
2022-Q3$1.5M$40M$497M$46M-$31M operating cash flowreport ↗
2022-Q2$1.3M$32M$510M$41M-$35M operating cash flowreport ↗
2022-Q1$1.1M$27M$544M$36M-$37M operating cash flowreport ↗
2021-Q3$139M$18M$601M—$112M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$9.7M$135M$308M$61M-$164M operating cash flowreport ↗

Prothena reported full-year 2025 revenue of $9.68M, down 92.8% YoY, with R&D spend of $134.85M, down 39.4% YoY. The company ended the year with $308.39M in cash and equivalents and reported a net loss of $244.09M.

For 2026, Prothena guided to full-year net cash used in operating and investing activities of $50–55M and approximately $255M ending cash at the midpoint, excluding potential milestone payments of up to $105M. Business highlights included partner Roche initiating the Phase 3 PARAISO trial for prasinezumab and Novo Nordisk initiating the Phase 3 CLEOPATTRA trial for coramitug, both with primary completion expected in 2029; Bristol Myers Squibb fully enrolling the Phase 2 TargetTau-1 trial for BMS-986446 and obtaining FDA Fast Track designation; and preclinical updates on TDP-43 CYTOPE and PRX012-TfR. Shareholders also approved a capital reduction to support a potential 2026 share redemption program.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$135M$223M$472M$31M-$150M operating cash flowreport ↗
2023-FY$91M$221M$621M$37M-$134M operating cash flowreport ↗
2022-FY$54M$136M$713M$29M-$109M operating cash flowreport ↗
2021-FY$201M$82M$580M—$93M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 21 purchases ($13.7M), 2 sales ($136K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-17SCULLY WILLIAM P · 10% ownerOpen-market purchase50,000$8.09$405KForm 4
2026-11-09SCULLY WILLIAM P · 10% ownerOpen-market purchase140,000$8.53$1.2MForm 4
2026-11-06SCULLY WILLIAM P · 10% ownerGift916,444——Form 4
2026-10-27SCULLY WILLIAM P · 10% ownerGift566,444——Form 4
2026-10-23SCULLY WILLIAM P · 10% ownerOpen-market purchase50,000$8.07$404KForm 4
2026-10-22SCULLY WILLIAM P · 10% ownerOpen-market purchase100,000$8.19$819KForm 4
2026-10-14SCULLY WILLIAM P · 10% ownerOpen-market purchase10,000$8.46$85KForm 4
2026-10-13SCULLY WILLIAM P · 10% ownerOpen-market purchase100,000$8.35$835KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 184 reporting institutions held 47.0M shares ($439.3M).

#InstitutionSharesValue
1FMR LLC7,551,218$73.4M
2Rubric Capital Management LP5,000,000$48.6M
3BlackRock, Inc.4,644,160$45.1M
4STATE STREET CORP1,938,498$18.8M
5D. E. Shaw & Co., Inc.1,763,347$17.1M
6ADAR1 Capital Management, LLC1,581,443$15.4M
7VANGUARD PORTFOLIO MANAGEMENT LLC1,445,979$14.1M
8MORGAN STANLEY1,230,448$12.0M
9Palo Alto Investors LP1,208,568$11.7M
10TWO SIGMA INVESTMENTS, LP1,205,978$11.7M
11GEODE CAPITAL MANAGEMENT, LLC1,098,166$10.7M
12FEDERATED HERMES, INC.1,059,849$10.3M
13JACOBS LEVY EQUITY MANAGEMENT, INC972,017$9.4M
14GOLDMAN SACHS GROUP INC818,885$8.0M
15DIMENSIONAL FUND ADVISORS LP782,603$7.6M